Latest California Healthline Stories
Pacientes con dolor crónico se sienten atrapados en el debate sobre opioides
Los pacientes que necesitan esta medicación se sienten afectados injustamente por la tendencia a recetarlos cada vez menos, como una estrategia para frenar la creciente epidemia de abuso de opioides.
Patients With Chronic Pain Feel Caught In An Opioid-Prescribing Debate
States are passing laws that limit a doctor’s ability to prescribe opioids. Doctors and patients alike are wrestling with what that means in cases of chronic pain.
Readers And Tweeters: On Seniors Packing Heat And When They Should Pack It In
California Healthline and Kaiser Health News give readers a chance to comment on a recent batch of stories.
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Facebook Live: The Marketing Plan That Fueled An Addiction Epidemic
Kaiser Health News senior correspondent Fred Schulte talks about a cache of files detailing Purdue Pharma’s early OxyContin marketing plan.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
What A U.S.-China Trade War Could Mean For The Opioid Epidemic
The nation’s effort to combat this public health crisis could get caught in the crossfire of the Trump administration’s trade policies.
Tennessee-Based Pain Management Group To Close Clinics Amid Financial Turmoil
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
Doling Out Pain Pills Post-Surgery: An Ingrown Toenail Not The Same As A Bypass
As the opioid epidemic rages, a Johns Hopkins surgeon and researcher is leading an effort to curb overprescribing by offering procedure-specific guidelines to ensure that post-surgical patients leave the hospital with enough, but not too much, pain medication.
How America Got Hooked On A Deadly Drug
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.